{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:18:56Z","timestamp":1790684336676,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jhep.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T16:34:02Z","timestamp":1471883642000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: A 5-year randomised study"],"prefix":"10.1016","volume":"66","author":[{"given":"Scott","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milotka","family":"Fabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijomir","family":"Pelemis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hie-Won","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin A.","family":"Caruntu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungpil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Kitrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Sporea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Yurdaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Husa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej S.","family":"Jablkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.08.008_b0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2016.08.008_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.008_b0020","unstructured":"European Medicines Agency. Epivir (lamivudine). Available at: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000107\/human_med_000767.jsp&mid=WC0b01ac058001d124. Date accessed: 12\/02\/2016."},{"key":"10.1016\/j.jhep.2016.08.008_b0025","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.008_b0030","unstructured":"World Health Organization 2015. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Available at: www.who.int\/iris\/handle\/10665\/154590#sthash.E2tZ8jX9.dpuf. Date accessed: 12\/02\/2016."},{"key":"10.1016\/j.jhep.2016.08.008_b0035","first-page":"777","article-title":"Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B","volume":"7","author":"Chao","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jhep.2016.08.008_b0040","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1128\/AAC.01742-13","article-title":"Efficacy of adefovir-based combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B virus infection","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.08.008_b0045","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.008_b0050","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.3748\/wjg.v18.i47.6987","article-title":"Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B","volume":"18","author":"Yun","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.08.008_b0055","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.cgh.2014.05.024","article-title":"No resistance to tenofovir disoproxil fumarate through 96weeks of treatment in patients with lamivudine-resistant chronic hepatitis B","volume":"12","author":"Corsa","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0060","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","article-title":"Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine resistant chronic hepatitis B","volume":"146","author":"Fung","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.008_b0065","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.04454-14","article-title":"Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.08.008_b0070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","volume":"40","author":"van B\u00f6mmel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.008_b0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy","volume":"44","author":"van B\u00f6mmel","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.008_b0080","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/AAC.02483-13","article-title":"Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B patients without detectable lamivudine resistance","volume":"58","author":"Lee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.08.008_b0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","article-title":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","volume":"60","author":"Berg","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0090","doi-asserted-by":"crossref","first-page":"e98865","DOI":"10.1371\/journal.pone.0098865","article-title":"Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis b virus infection: a systematic review and meta-analysis","volume":"9","author":"Ke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.08.008_b0095","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.08.008_b0100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotransferase levels in the United States","volume":"98","author":"Clark","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.08.008_b0105","doi-asserted-by":"crossref","unstructured":"Jacobson IM, Washington MK, Thompson A, et al. Presence of steatosis and HBeAg-positive status are independently associated with persistently elevated serum ALT levels in chronic HBV patients during antiviral therapy. 49th Annual Meeting of the European Association for the Study of the Liver; April 9\u201313 2014; London, UK; Poster #1084.","DOI":"10.1016\/S0168-8278(14)61244-7"},{"key":"10.1016\/j.jhep.2016.08.008_b0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jvh.12358","article-title":"Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-na\u00efve chronic hepatitis B patients in the real-world setting","volume":"22","author":"Idilman","year":"2015","journal-title":"Viral Hepat"},{"key":"10.1016\/j.jhep.2016.08.008_b0115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.08.008_b0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1542-3565(04)00017-5","article-title":"Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B","volume":"2","author":"Kuo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0125","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.12108","article-title":"Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice","volume":"28","author":"Lin","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.008_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van B\u00f6mmel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.008_b0140","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"Marcellin","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3350\/cmh.2014.20.3.267","article-title":"Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir","volume":"20","author":"Ze","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2016.08.008_b0150","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1365-2036.2011.04833.x","article-title":"Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir","volume":"34","author":"Ong","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.08.008_b0155","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.008_b0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.008_b0165","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany","volume":"61","author":"Petersen","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.08.008_b0170","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","article-title":"Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters","volume":"91","author":"Kohler","year":"2011","journal-title":"Lab Invest"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T20:30:42Z","timestamp":1771965042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816304408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0168827816304408"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.08.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: A 5-year randomised study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}